Loading
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (31 ops.)
Latest filing published 10 Sept 2026 for Protagonist Therapeutics, Inc, €1.0M.
Filing timeline
BuySaleDinesh V. Ph D. Patel
Insider track record
Disclosed buys
2
Disclosed sells
31
Signal history
Closed purchases
Market purchases
2
Positive at T+90
0%
Median T+90
-1.6%
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +162.6%Entry US$8.11 · Close at T+365 US$21.30
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Dinesh V. Ph D. Patel: trading record in brief
Dinesh V. Ph D. Patel is a declared insider of Protagonist Therapeutics, Inc (chief executive), with filings sourced from SEC (Form 4). Over a trading history stretching from 10 March 2017 to 10 September 2026, the count stands at 98 filings.
On the open market, the record shows 2 purchases worth €152k and 31 sales worth €52.1M. The net balance comes to €52.0M on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 15 share grants and 33 option exercises. 2026 to date brings no purchases and 12 sales.
The newest entry dates from 10 September 2026: an option exercise of €1.0M, in Protagonist Therapeutics, Inc. The latest purchase dates back some time: it was published 2,516 days ago, on 3 December 2019. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Dinesh V. Ph D. Patel
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations98 total
54,174 shares@ US$21.580.012% mcap2.2% of flowCommon StockSEC:0001104659-26-106831:0
54,174 shares@ US$145.870.084% mcap14.7% of flowCommon StockSEC:0001104659-26-106831:1
63,548 shares@ US$21.580.015% mcap2.5% of flowCommon StockSEC:0001104659-26-106831:2
63,548 shares@ US$146.180.099% mcap17.2% of flowCommon StockSEC:0001104659-26-106831:3
7,278 shares@ US$21.580.0017% mcap0.3% of flowCommon StockSEC:0001104659-26-106831:4
7,278 shares@ US$144.100.011% mcap1.9% of flowCommon StockSEC:0001104659-26-106831:5
510 shares0Common StockSEC:0001104659-26-105955:0
65,761 shares@ US$21.580.015% mcap2.6% of flowCommon StockSEC:0001104659-26-095111:0
34,239 shares@ US$21.580.0079% mcap1.4% of flowCommon StockSEC:0001104659-26-095111:2
34,239 shares@ US$148.520.055% mcap9.5% of flowCommon StockSEC:0001104659-26-095111:3
65,761 shares@ US$149.110.11% mcap18.3% of flowCommon StockSEC:0001104659-26-095111:1
75,000 shares@ US$21.580.016% mcap3.0% of flowCommon StockSEC:0001104659-26-061476:0
1,460 shares0Common StockSEC:0001104659-26-048572:0
59 shares@ US$8.580.0% of flowCommon StockSEC:0001104659-26-034736:1
59 shares@ US$101.000.0% of flowCommon StockSEC:0001104659-26-034736:2
54,641 shares@ US$8.580.7% of flowCommon StockSEC:0001104659-26-034736:3
54,641 shares@ US$101.007.9% of flowCommon StockSEC:0001104659-26-034736:4
50,000 shares0Common StockSEC:0001104659-26-034736:0
19,315 shares@ US$4.21Common StockSEC:0001104659-26-007129:1
19,315 shares@ US$84.59Common StockSEC:0001104659-26-007129:2
10,685 shares@ US$4.21Common StockSEC:0001104659-26-007129:3
10,685 shares@ US$84.00Common StockSEC:0001104659-26-007129:4
14,205 shares@ US$21.58Common StockSEC:0001104659-26-007129:5
14,205 shares@ US$84.05Common StockSEC:0001104659-26-007129:6
4,068 shares@ US$21.58Common StockSEC:0001104659-26-007129:7
25 of 98 declarations
